bn 80927 has been researched along with camptothecin in 6 studies
*Camptothecin: An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity. [MeSH]
*Camptothecin: An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity. [MeSH]
| Studies (bn 80927) | Trials (bn 80927) | Recent Studies (post-2010) (bn 80927) | Studies (camptothecin) | Trials (camptothecin) | Recent Studies (post-2010) (camptothecin) |
|---|---|---|---|---|---|
| 6 | 1 | 1 | 13,002 | 2,229 | 5,391 |
| Protein | Taxonomy | bn 80927 (IC50) | camptothecin (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 0.05 | |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | 7.4 | |
| DNA topoisomerase 1 | Homo sapiens (human) | 1.9799 | |
| Somatostatin receptor type 1 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 2 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 4 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 3 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 5 | Homo sapiens (human) | 0.0022 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.97 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.05 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 9 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.05 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bigg, DC; Coulomb, H; Demarquay, D; Harnett, J; Huchet, M; Lanco, C; Lavergne, O; Lesueur-Ginot, L; Rolland, A | 1 |
| Bigg, D; Camara, J; Coulomb, H; Demarquay, D; Huchet, M; Lavergne, O; Lesueur-Ginot, L | 1 |
| Bigg, D; Carlson, M; Coulomb, H; Demarquay, D; Huchet, M; Kasprzyk, P; Lauer, J; Lavergne, O | 1 |
| Bigg, DC; Camara, J; Coulomb, H; Demarquay, D; Huchet, M; Kasprzyk, PG; Lavergne, O; Lesueur-Ginot, L; Prévost, G | 1 |
| Yang, S; Zhang, WN | 1 |
| Cendrós, JM; Cvitkovic, F; Delavault, P; Lesimple, T; Obach, R; Peraire, C; Perez-Mayoral, A; Principe, P; Pruñonosa, J; Soto, E; Trocóniz, IF | 1 |
1 review(s) available for bn 80927 and camptothecin
| Article | Year |
|---|---|
[Homocamptothecins--novel promising anticancer drugs as inhibitors of topoisomerase I].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; DNA Damage; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 2004 |
1 trial(s) available for bn 80927 and camptothecin
| Article | Year |
|---|---|
Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genotype; Humans; Infusions, Intravenous; Leukocyte Count; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Neoplasms; Neutrophils; Tandem Mass Spectrometry; Treatment Outcome | 2012 |
4 other study(ies) available for bn 80927 and camptothecin
| Article | Year |
|---|---|
BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II.
Topics: Antineoplastic Agents; Camptothecin; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1999 |
The homocamptothecin, BN 80927, is a potent topoisomerase I poison and topoisomerase II catalytic inhibitor.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Catalysis; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Nucleic Acid Synthesis Inhibitors; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2000 |
The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Enzyme Inhibitors; Growth Inhibitors; Humans; Irinotecan; Male; Mice; Prostatic Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Camptothecin; Cell Division; Cell Line, Tumor; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Superhelical; Drug Screening Assays, Antitumor; Drug Stability; Enzyme Inhibitors; HL-60 Cells; Humans; K562 Cells; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Xenograft Model Antitumor Assays | 2004 |